Abstract
Get full access to this article
View all access options for this article.
References
1.
Turner
JR
. Editor’s commentary: celebrating the journal’s new name—Therapeutic Innovation & Regulatory Science
. Drug Information Journal . 2012 ;46 (4 ):391 .
2.
Hamburg
MA
. Remarks at the National Press Club speaker luncheon, October 6, 2010 . http://www.fda.gov/NewsEvents/Speeches/ucm229195.htm. Accessed July 17, 2012 .
3.US Food and Drug Administration . Advancing regulatory science for public health: a framework for FDA’s regulatory science initiative . http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131.htm. Published October 2010. Accessed July 17, 2012 .
4.US Food and Drug Administration . Advancing regulatory science at the FDA: a strategic plan . http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm. Published August 2011. Accessed July 17, 2012 .
5.European Medicines Agency website . http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000479.jsp&mid=WC0b01ac058026369c. Accessed July 17, 2012 .
6.
Tominaga
T
Asahina
Y
Uyama
Y
Kondo
T
. Regulatory science as a bridge between science and society . Clin Pharmacol Ther . 2011 ;90 :29 –31 .
7.
Cooper
CK
Buckman-Garner
S
Slack
MA
Florian
JA
McCune
S.
Developing standardized data: connecting the silos . Drug Information Journal . 2012 ;46 (5 ):521 –522 .
8.
Rosario
LA
Kropp
TJ
Wilson
SE
Cooper
CK.
Join FDA/PhUSE Working Groups to help harness the power of computational science . Drug Information Journal . 2012 ;46 (5 ):523 –524 .